Skip to main content

Cefoxitin Side Effects

Medically reviewed by Drugs.com. Last updated on Feb 18, 2024.

Applies to cefoxitin: intravenous powder for solution, intravenous solution.

Serious side effects of Cefoxitin

Along with its needed effects, cefoxitin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking cefoxitin:

More common

Rare

Incidence not known

Other side effects of Cefoxitin

Some side effects of cefoxitin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

For Healthcare Professionals

Applies to cefoxitin: injectable powder for injection, intravenous powder for injection, intravenous solution.

Local

Common (1% to 10%): Induration, pain, pain in the infused vein, phlebitis, tenderness, thrombophlebitis, vein erythema, vein exudates, vein induration[Ref]

Phlebitis and thrombophlebitis occurred with IV administration.

Induration, pain, and tenderness occurred in of patients who received IM administration.[Ref]

Dermatologic

Common (1% to 10%): Maculopapular rash, rash/skin rashes, urticaria

Frequency not reported: Acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme, exfoliative dermatitis, pruritus, severe cutaneous adverse reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis[Ref]

Gastrointestinal

Rare (0.01% to 0.1%): Diarrhea, nausea, vomiting

Frequency not reported: Abdominal pain, colitis, pseudomembranous colitis[Ref]

Pseudomembranous colitis may occur during or after treatment.[Ref]

Hematologic

Frequency not reported: Agranulocytosis, anemia, aplastic anemia, bone marrow depression, eosinophilia, granulocytopenia, hemolytic anemia, leukocytosis, leukopenia, neutropenia, pancytopenia, positive direct Coombs test, prolonged prothrombin time, thrombocytopenia[Ref]

Renal

Rare (0.01% to 0.1%): Acute renal failure

Frequency not reported: Elevation in blood urea nitrogen (BUN), elevation in serum creatinine, interstitial nephritis, prerenal azotemia, renal dysfunction, toxic nephropathy[Ref]

Hepatic

Frequency not reported: Cholestasis, elevated bilirubin, jaundice, liver dysfunction, transient elevations in ALT/AST/serum alkaline phosphatase[Ref]

Cardiovascular

Frequency not reported: Flushing, hemorrhage, hypotension[Ref]

Hypersensitivity

Allergic reactions included anaphylaxis, angioedema, dyspnea, eosinophilia, fever, flushing, interstitial nephritis, pruritus, and skin reactions (e.g., exfoliative dermatitis, maculopapular rash, rash, toxic epidermal necrolysis, urticaria). Anaphylaxis rarely led to death.[Ref]

Frequency not reported: Anaphylaxis, angioedema, other allergic reactions[Ref]

Immunologic

Frequency not reported: Serum sickness-like reaction, superinfection[Ref]

Other

Frequency not reported: Death, fever[Ref]

Metabolic

Frequency not reported: False positive for urinary glucose, transient elevation in LDH[Ref]

Genitourinary

Frequency not reported: Vaginitis, vaginitis candidiasis[Ref]

Nervous system

Frequency not reported: Seizures[Ref]

Musculoskeletal

Frequency not reported: Myasthenia gravis exacerbation[Ref]

Respiratory

Frequency not reported: Dyspnea[Ref]

References

1. Product Information. Mefoxin (cefoxitin). Merck & Co., Inc. 2002;PROD.

2. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.